News

02 April 2013

Regulatory changes in the procedure of expert review and registration of new drugs are needed towards localization of innovative pharmaceutical products in Russia – Vladimir Gurdus

"To improve quality and safety of new drugs to be introduced to the Russian market and for localization of innovative pharmaceutical products in the country, the expert review and registration of such products require procedural changes”, - Vladimir Gurdus, CEO of D-Pharma, LLC, a managing company of RMI and NovaMedica projects stated at the Conference “State regulation and the Russian pharmaceutical industry 2013: continuation of the dialogue”.

26 March 2013

Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry – Mikhail Getman

"Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry”, - said Mikhail Getman, VP for R&D and Regulatory Affairs of NovaMedica, LLC at the 1^st meeting of the Subcommittee for international cooperation in modernization and innovations in healthcare and pharmaceutical industry of the Russian Chamber of Commerce and Trade.

20 December 2012

Financing Deal of the Year Nominee: Rusnano/Domain and CoDa Therapeutics

Wendy Diller, The IN VIVO Blog

How about voting for a deal that turns conventional wisdom on its head.
The biopharma industry has looked to emerging markets for near-term revenues and cost efficiencies, but not for scientific or commercial innovation. An umbrella deal between Rusnano and the US venture capital firm Domain Associates, announced in March, and a subsequent tie up with Domain portfolio company CoDa Therapeutics, goes some way toward erasing those misperceptions. At the same time, the partners’ tie up reflects sovereign funds’ increasingly important role in shaping the life sciences industry.

RMI and Domain Associates to invest $93m in development of three next-generation pharmaceuticals

U.S. venture capital firm Domain Associates, Rusnano subsidiary RusnanoMedInvest (RMI) and a group of co-investors will invest a combined $93m in Marinus Pharmaceuticals, Inc., Lithera, Inc., and Regado Biosciences, Inc., all of which are developers of advanced pharmaceutical products.

01 October 2012

Special autumn session for the pharmaceutical business leaders

Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive cluster of venture investors in the sector here in Russia.

24 July 2012

Domain Associates & RMI announce first joint investment

Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm, and RusnanoMedInvest (RMI), a subsidiary of RUSNANO, today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ). 

21 June 2012

St. Petersburg International Economic Forum

Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets

06 March 2012

RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.